MYQORZO DIN 02572729
Health Canada record
| Active ingredient(s) | AFICAMTEN 15 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION RECOMMENDED |
| Class | Human |
| ATC | |
| Original market date | |
| Current status date | 14-Oct-2026 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AFICAMTEN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02572710 | MYQORZO | CYTOKINETICS, INCORPORATED | Tablet | AFICAMTEN 10 MG | Approved |
| 02572737 | MYQORZO | CYTOKINETICS, INCORPORATED | Tablet | AFICAMTEN 20 MG | Approved |
| 02572702 | MYQORZO | CYTOKINETICS, INCORPORATED | Tablet | AFICAMTEN 5 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38476 | 2026-10-14 | New Drug Submission (NDS) |